Join
Live feed
·
PRReleasevia Quantisnow
Alnylam Pharmaceuticals Inc. logo

Alnylam to Present Full 18-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran at the Société Francophone du Nerf Périphérique Annual Meeting

ByQuantisnow·Wall Street's wire, on your screen.
ALNY· Alnylam Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ALNY (Alnylam Pharmaceuticals Inc.) and more on Quantisnow.